MTOR and leukemia: Alternatively, presence of cGVHD and use of Sir may be protective against AML relapse due to the enhanced graft-versus-leukemia effect conferred by cGVHD [33] and inhibition of the mTOR pathway by Sir [34], especially in high-risk patients [35].